Cellectar BiosciencesCLRB
About: Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Employees: 11
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
367% more call options, than puts
Call options by funds: $14K | Put options by funds: $3K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
14% less funds holding
Funds holding: 35 [Q3] → 30 (-5) [Q4]
26.78% less ownership
Funds ownership: 39.13% [Q3] → 12.35% (-26.78%) [Q4]
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
95% less capital invested
Capital invested by funds: $30M [Q3] → $1.53M (-$28.5M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CLRB.
Financial journalist opinion
Based on 4 articles about CLRB published over the past 30 days









